Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
Ligand Pharmaceuticals (Nasdaq: LGND) has announced plans to host an Investor and Analyst Day in Boston on December 10, 2024, from 10:30 a.m. to 12:00 p.m. Eastern Time. The event will feature presentations from senior management covering company strategy, investment activities, royalty portfolio, and long-term financial outlook. Key features include an in-person format, a live Q&A session, and accessibility via webcast through Ligand's Investor Relations website. A replay will be available after the event.
Ligand Pharmaceuticals (Nasdaq: LGND) ha annunciato l'intenzione di ospitare un Investor and Analyst Day a Boston il 10 dicembre 2024, dalle 10:30 alle 12:00 ora orientale. L'evento includerà presentazioni da parte della direzione senior che tratteranno la strategia aziendale, le attività di investimento, il portafoglio di royalties e le prospettive finanziarie a lungo termine. Caratteristiche chiave includono un formato in presenza, una sessione di domande e risposte dal vivo e accessibilità tramite webcast attraverso il sito web delle Relazioni con gli Investitori di Ligand. Una registrazione sarà disponibile dopo l'evento.
Ligand Pharmaceuticals (Nasdaq: LGND) ha anunciado planes para llevar a cabo un Día del Inversor y Analista en Boston el 10 de diciembre de 2024, de 10:30 a.m. a 12:00 p.m. hora del Este. El evento contará con presentaciones de la alta dirección que cubrirán la estrategia de la empresa, las actividades de inversión, la cartera de regalías y las perspectivas financieras a largo plazo. Características clave incluyen un formato en persona, una sesión de preguntas y respuestas en vivo, y accesibilidad a través de webcast en el sitio web de Relaciones con Inversores de Ligand. Se dispondrá de una repetición después del evento.
리간드 제약 (Nasdaq: LGND)는 2024년 12월 10일 오전 10:30부터 오후 12:00까지 동부 표준시 기준으로 보스턴에서 투자자 및 분석가의 날을 개최할 계획을 발표했습니다. 이 이벤트에서는 회사 전략, 투자 활동, 로열티 포트폴리오 및 장기 재무 전망을 다룬 고위 경영진의 발표가 포함됩니다. 주요 특징으로는 대면 형식, 실시간 Q&A 세션, 리간드의 투자자 관계 웹사이트를 통한 웹캐스트 접근성이 있습니다. 이벤트 후 다시 보기 기능이 제공될 것입니다.
Ligand Pharmaceuticals (Nasdaq: LGND) a annoncé des plans pour organiser un Journée des Investisseurs et des Analystes à Boston le 10 décembre 2024, de 10h30 à 12h00 heure de l'Est. L'événement comprendra des présentations de la direction senior portant sur la stratégie de l'entreprise, les activités d'investissement, le portefeuille de redevances et les perspectives financières à long terme. Les caractéristiques clés incluent un format en personne, une session de questions-réponses en direct et une accessibilité via webcast sur le site Web des relations avec les investisseurs de Ligand. Un enregistrement sera disponible après l'événement.
Ligand Pharmaceuticals (Nasdaq: LGND) hat Pläne angekündigt, am 10. Dezember 2024 von 10:30 bis 12:00 Uhr Eastern Time in Boston einen Investor and Analyst Day auszurichten. Die Veranstaltung wird Präsentationen des oberen Managements enthalten, die die Unternehmensstrategie, Investitionsaktivitäten, das Lizenzportfolio und die langfristigen Finanzprognosen abdecken. Wichtige Merkmale umfassen ein persönliches Format, eine Live-Q&A-Session und die Zugänglichkeit über Webcast über die Investor Relations-Website von Ligand. Eine Aufzeichnung wird nach der Veranstaltung verfügbar sein.
- None.
- None.
The in-person event will include presentations from Ligand’s senior management team highlighting the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook. A live question and answer session will follow the formal presentation. Investors and analysts can register for the event here.
A live webcast of the event will be accessible through Ligand’s Investor Relations website at investor.ligand.com. A webcast replay will be available following the conclusion of the event.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101509872/en/
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
LifeSci Advisors
Bob Yedid
bob@lifesciadvisors.com
(516) 428-8577
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
Source: Ligand Pharmaceuticals Incorporated
FAQ
When is Ligand's (LGND) Investor Day 2024?
How can I watch Ligand's (LGND) 2024 Investor Day presentation?
What topics will be covered at Ligand's (LGND) 2024 Investor Day?
Will there be a replay available of Ligand's (LGND) 2024 Investor Day?
